Generic versions of montelukast (marketed as Singulair) have received FDA approval, the agency announced.

The orally administered leukotriene receptor antagonist is used to control symptoms of asthma and allergies, although the FDA warns that montelukast should not be used for relief of sudden asthma attacks. The agency also urges patients to contact clinicians immediately if mood or behavioral changes occur with the drug.

Source: FDA news